Bedsore treatment
The IL-33 inhibitor in the therapeutic agent prevents pressure ulcer formation and promotes healing by inhibiting IL-33 activity, addressing the limitations of existing treatments.
Patent Information
- Application Number
- JP2020119951
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-07-13
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2040-07-13
AI Technical Summary
Existing treatments for pressure ulcers, such as basic FGF sprays and prostaglandin ointments, are ineffective in preventing ulcer formation and difficult to heal once formed, especially in patients with poor general conditions.
A therapeutic agent containing an IL-33 inhibitor, such as an anti-IL-33 neutralizing antibody or ST2 neutralizing antibody, is administered to inhibit IL-33 activity, thereby preventing pressure ulcer formation and promoting healing.
The IL-33 inhibitor effectively suppresses pressure ulcer formation and progression, allowing for early treatment and prevention, even in patients with poor general health, by inhibiting IL-33 activity.
Smart Images

Figure 0007578943000001 
Figure 0007578943000002 
Figure 0007578943000003
Abstract
Description
[Technical field]
[0001] In particular, the present invention relates to a treatment for bedsores, a method for treating bedsores, and a method for preventing bedsores. [Background technology]
[0002] Bedsores are intractable skin ulcers that develop in areas where weight bearing has been applied for long periods of time due to prolonged bed rest. In recent years, treatment and prevention methods for bedsores have become widely known, and the frequency and severity of bedsores have been somewhat reduced thanks to cross-disciplinary efforts within hospitals and reviews of insurance treatment. However, in countries like Japan, where the proportion of elderly people in the population is rapidly increasing, the number of bedsore patients is steadily increasing.
[0003] In bedsores, erythema appears at the pressure site, and the skin gradually necrotizes and develops into an ulcer. In such cases, the only option is to treat the skin ulcer after it has formed. To date, basic FGF spray, prostaglandin ointment, and wound dressings have been developed as treatments for this. However, once a bedsore has formed, it is very difficult to cure it, and since the patient's overall condition is often poor, surgical treatment is also often difficult.
[0004] Here, referring to Patent Document 1, as a conventional medicine for inflammation-related disorders, Zn 2+ or Ga 3+ or a complex of nocardamine (desferrioxamine E) with silver or gold or any combination thereof. Further, the pharmaceutical composition can be used to regulate cytokine levels and treat inflammation-related disorders. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2020-23558 A Summary of the Invention [Problem to be solved by the invention]
[0006] However, the pharmaceutical composition of Patent Document 1 could not prevent the formation of ulcers in bedsores, which is a gradual transformation of erythema at the pressure site into an ulcer.
[0007] The present invention has been made in view of the above circumstances, and an object of the present invention is to solve the above-mentioned problems. [Means for solving the problem]
[0008] The pressure ulcer treatment agent of the present invention contains an IL-33 inhibitor that inhibits the action of IL-33 (Interleukin-33). The IL-33 inhibitor is an anti-IL-33 neutralizing antibody, an IL-33 binding site of ST2, and an anti-ST2 neutralizing antibody. It is characterized by: In the therapeutic agent for bedsore of the present invention, the IL-33 inhibitor is characterized by inactivating extracellular IL-33 or inactivating an IL-33 receptor on the cell membrane. In the therapeutic agent for bedsore of the present invention, the IL-33 inhibitor comprises an IL-33 activity inhibitor or an IL-33 expression inhibitor. In the bedsore therapeutic agent of the present invention, the IL-33 receptor is The above It is characterized by being ST2. In the treatment for bedsore of the present invention, the IL-33 inhibitor comprises an inactivator of ST2. The therapeutic agent for bedsore of the present invention is characterized in that it is administered prophylactically before the formation of a bedsore ulcer, or administered for treatment after the development of an ulcer. Effect of the Invention
[0009] According to the present invention, a therapeutic agent for bedsores that can prevent the formation of ulcers in bedsores can be provided by incorporating an IL-33 inhibitor that inhibits the action of IL-33 (Interleukin-33). [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 is a conceptual diagram showing the role of IL-33 and ST2 in inflammation according to an embodiment of the present invention. [Diagram 2] FIG. 1 is a conceptual diagram of treatment of a bedsore model mouse according to an embodiment of the present invention. [Diagram 3] 1 shows photographs illustrating the suppression of bedsore formation in IL-33 knockout mice according to an example of the present invention. [Figure 4] 1 is a graph showing the results of suppressing bedsore formation in IL-33 knockout mice according to an example of the present invention. [Diagram 5] 1 shows photographs showing the suppression of bedsore formation in ST2 transgenic mice according to an example of the present invention. [Figure 6] 1 is a graph showing the results of suppressing bedsore formation in ST2 transgenic mice according to an example of the present invention. [Figure 7] 1 shows photographs showing the inhibition of bedsore formation by administration of an IL-33 neutralizing antibody according to an example of the present invention. [Figure 8] 1 is a graph showing the results of suppressing bedsore formation by administration of an IL-33 neutralizing antibody according to an example of the present invention. [Figure 9] 1 shows photographs showing the inhibition of bedsore formation by administration of an ST2 neutralizing antibody according to an example of the present invention. [Figure 10] 1 is a graph showing the results of suppressing bedsore formation by administration of an ST2 neutralizing antibody according to an example of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] <Embodiment Mode> As mentioned above, bedsore is a difficult-to-treat skin ulcer that occurs at the site where weight load is applied for a long time due to long-term bed rest. In bedsore, the pressure-loaded site first becomes erythematous, and gradually the skin necroses and an ulcer is formed. Conventionally, the treatment of bedsore has been to treat the skin ulcer after the ulcer is formed, and it is very difficult to cure it conservatively, and in many cases, surgical treatment is also difficult. For this reason, the present inventors used a mouse model of bedsore to study the involvement of IL-33 (Interleukin-33), one of the inflammatory cytokines, in the pathology of ulcers. In this study, the present inventors considered the possibility that IL-33 may also promote the healing process of bedsores, based on the results of previous studies on IL-33. However, after the start of the experiment, it was revealed that the formation of bedsores itself was significantly suppressed in IL-33 knockout mice. This was a surprising result that could not be predicted by those skilled in the art. In other words, it is believed that IL-33 plays an important role in the formation stage of skin ulcers caused by pressure load, and the present inventors came up with the idea of suppressing the development of bedsores by inhibiting IL-33. In fact, they found that the formation of bedsores can be suppressed by inhibiting the action of IL-33 at the pressure-loaded site, and thus completed the present invention.
[0012] In the present embodiment, a pressure ulcer treatment agent containing an inhibitor that inhibits the action of IL-33 makes it possible to preventively suppress or cure pressure ulcer formation during the ulcer formation stage following pressure load. The bedsore treating agent, the bedsore treating method, and the bedsore preventing method of this embodiment will be described in detail below.
[0013] [Treatment agent for bedsores] The pressure ulcer treating agent (medicine, medical composition, therapeutic composition) of this embodiment is characterized by containing an inhibitor that inhibits the action of IL-33 (hereinafter referred to as "IL-33 inhibitor"). Here, the bedsore (pressure sore) in this embodiment is a skin disease also known as "bed sores". Bed sores are caused by external forces such as pressure, stretching, and friction on the skin and soft tissues around physiological bony prominences of the human body, which results in necrosis due to ischemia and reperfusion injury, resulting in skin ulcers. This ischemia and reperfusion injury is a phenomenon in which the injury progresses when blood circulation that has been temporarily cut off is restored. Specifically, erythema appears at the pressure site, and the skin gradually necroses and becomes ulcerated. In addition, in this embodiment, the term "bedsore" in the broad sense also includes mild skin disorders such as redness (erythema) and skin sores caused by external forces such as pressure, stretching, friction, etc., which have the same mechanism of action as bedsores. Such skin disorders also include, for example, skin disorders caused by pressure from a mask string or belt for a long period of time.
[0014] Next, IL-33 of this embodiment will be described. Explaining with reference to FIG. 1, IL-33 in this embodiment is an inflammatory cytokine of the IL-1 family member, and is constitutively expressed in the nuclei of vascular endothelial cells and epithelial cells. IL-33 is released from the nucleus when cells undergo necrosis due to invasive stimuli such as infection, physical or chemical stimuli, or stress. As a result, IL-33 stimulates immune cells such as group 2 innate lymphoid cells, thereby activating the immune system and inducing inflammation. That is, IL-33 is considered to function as an alarmin or DAMP (Damage Associated Molecular Pattern, alarm factor), which is an endogenous substance that immediately induces various types of inflammation. IL-33 is also produced in mast cells, dendritic cells, macrophages, fibroblasts, synovial cells, and the like. The membrane-bound ST2 protein (ST2L) is known to be a receptor for IL-33. ST2 is expressed in Th2 cells, mast cells, basophils, eosinophils, macrophages, dendritic cells, NK cells, NKT cells, type 2 innate lymphocytes, etc. In addition, IL-33 is known to affect the transcription of other genes as a nuclear factor.
[0015] Specifically, the IL-33 inhibitor of this embodiment may be an inhibitor of IL-33 activity. This IL-33 activity inhibitor is a composition that has the effect of regulating the activity of IL-33 inside and outside the cell. This IL-33 activity inhibitor includes, for example, a protein, peptide, nucleic acid, PNA (peptide nucleic acid), or other synthetic molecule that binds to IL-33 or inactivates or degrades IL-33 itself. Specifically, this protein or peptide includes an IL-33 neutralizing antibody that inhibits binding to the receptor, a peptide similar or similar to the IL-33 binding site of the receptor ST2, an IL-33-specific decomposition enzyme, a cleavage enzyme, and the like. More specifically, a neutralizing antibody such as an IL-33 monoclonal antibody as described in the Examples below is preferably included. In addition, this IL-33 neutralizing antibody may be an antibody-like peptide or PNA that has been truncated (shortened) to change the molecular weight, or that has been added with various tag molecules or that has been modified. Furthermore, the IL-33 activity inhibitor may be a peptide composition such as a synthetic inactive IL-33-like peptide or a peptide containing the ST2 binding site of IL-33.
[0016] Furthermore, the IL-33 inhibitor of this embodiment may be an active inhibitor that inhibits the outflow of translated IL-33 into body fluids in a broad sense, so as to prevent it from being released outside the cell due to necrosis and diffusing into the blood. Examples of this type of inhibitor include proteases that selectively degrade proteins in the nucleus, nuclear membrane protectors, and apoptosis promoters.
[0017] Alternatively, the IL-33 inhibitor of this embodiment may be an IL-33 expression inhibitor. The IL-33 expression inhibitor may be, for example, a nucleic acid such as RNA, DNA, or TNA (threose nucleic acid) that suppresses the expression, processing, translation, modification of the translation product, etc. of the IL-33-related gene in a bedsore in the body. Among these, the RNA or DNA may be configured to make it difficult to generate complete mRNA of the IL-33-related gene, such as RNAi, siRNA, shRNA, miR RNAi, ribozyme, antisense RNA, or other RNA with catalytic activity or RNAase decomposition activity. Alternatively, the RNA or DNA may be a sequence similar to IL-33 that does not produce activity, or other antagonistic base sequence, etc., that is introduced into cells to make it difficult to generate complete translation products of IL-33. Alternatively, the IL-33 inhibitor may be one that prevents the expression or conditional expression of the IL-33-related gene by retrovirus, genome editing, etc. Furthermore, genes, gene products, agonists / antagonists, and other compositions that act via pathways that are the targets of IL-33 expression regulation can also be used as IL-33 expression inhibitors.
[0018] Alternatively, the IL-33 inhibitor of this embodiment may inactivate the IL-33 receptor (receptor) on the cell membrane. In this case, the IL-33 inhibitor of this embodiment may target ST2 as the IL-33 receptor, as described above. In this case, the IL-33 inhibitor of this embodiment may contain an inactivator of ST2. Specifically, an ST2 neutralizing antibody can be used as the inactivator of ST2. As with the IL-33 neutralizing antibody, these ST2 neutralizing antibodies may also be antibody-like peptides, PNAs, peptide compositions, etc. Alternatively, the inactivator of ST2 may be a small-molecule organic compound that inactivates ST2. These inactivators of ST2 act, for example, by binding to the IL-33 binding site of ST2 or other extracellular sites, etc., to prevent IL-33 from binding to ST2. Alternatively, an ST2 inactivator may be configured to inhibit the action of IL-33 by overexpressing ST2 to reduce the effect per concentration of IL-33, as shown in the ST2 transgenic mouse in the Examples described below, or by blocking signal transduction via the intracellular domain of ST2. In addition to ST2, an inhibitor against the nuclear receptor of IL-33 can also be used as the IL-33 receptor.
[0019] When nucleic acids are used as these IL-33 inhibitors, the vehicle may be, for example, a plasmid or a viral vector. The viral vector may be constructed using a virus commonly known to those skilled in the art, such as an adenovirus, an adeno-associated virus, or a retrovirus.
[0020] The pressure ulcer treatment agent according to the embodiment of the present invention may contain any pharma- ceutically acceptable carrier. The carrier may be, for example, a liposome carrier, colloidal gold particles, a polypeptide, a lipopolysaccharide, a polysaccharide, a lipid membrane, or the like. Among these, it is preferable to use a carrier that improves the effect of an IL-33 inhibitor. For example, for nucleic acids, it is preferable to use liposomes, particularly cationic liposomes.
[0021] Furthermore, the pharma- ceutically acceptable carrier may contain, for example, physiological saline, an isotonic solution containing glucose or other auxiliary drugs, for example, D-sorbitol, D-mannose, D-mannitol, sodium chloride, etc. Furthermore, it is possible to administer the composition together with a suitable solubilizing agent, for example, alcohol, specifically ethanol, polyalcohol, for example, propylene glycol, polyethylene glycol, nonionic surfactant, for example, polysorbate 80, HCO-50, etc. Furthermore, the composition may further contain a suitable excipient, etc.
[0022] The pressure ulcer treatment agent of the present embodiment may also contain a suitable pharma- ceutically acceptable carrier to prepare a pharma- ceutically acceptable carrier. The carrier may contain a biocompatible material such as silicone, cellulose, agarose, pectin, petrolatum, various oils and fats, gelatin, collagen, arginine, other proteins, amino acids, etc. The carrier may also be provided as an emulsion. Furthermore, the agent may contain any one or any combination of pharmaceutical additives such as diluents, flavorings, preservatives, excipients, disintegrants, lubricants, binders, emulsifiers, plasticizers, etc. These carriers or supports may be added to provide the treatment for bedsore of the present embodiment as a liniment, ointment, patch, or wound dressing (hereinafter simply referred to as "liniment"). In this case, these carriers or supports may be configured to release the IL-33 inhibitor from vascular endothelial cells or epithelial cells associated with bedsores when pressure is applied.
[0023] In addition, the pressure ulcer treatment agent of the present embodiment can be used in combination with other compositions other than the IL-33 inhibitor. The composition of the present embodiment may be administered simultaneously with the other composition, or may be administered at an interval, with no particular restriction on the order of administration. In addition, in an embodiment of the present invention, the period during which the disease is improved or alleviated is not particularly limited, but may be temporary improvement or alleviation, or improvement or alleviation for a certain period of time.
[0024] [Method for treating bedsores and method for preventing bedsores] A method for treating a bedsore according to an embodiment of the present invention is characterized in that an IL-33 inhibitor that inhibits the action of IL-33 (Interleukin-33) is administered (however, medical procedures are excluded). Specifically, in the method for treating bedsore according to an embodiment of the present invention, the above-mentioned IL-33 inhibitor is administered after pressure load or after the onset of erythema, making it possible to suppress the development of skin ulcers due to bedsores.
[0025] The administration route of the pressure ulcer treatment agent according to the embodiment of the present invention is not particularly limited, and it can be administered parenterally or orally. Parenteral administration can be, for example, intravenous, intraarterial, subcutaneous, intradermal, intramuscular, or intraperitoneal administration, or it can be directly applied to the skin or administered by penetration through pasting. The therapeutic agent for bedsore according to the embodiment of the present invention can be formulated using pharma- ceutically acceptable carriers well known in the art in an administration form suitable for parenteral or oral administration. When the pressure ulcer treating agent according to the embodiment of the present invention is administered parenterally, it can be administered subcutaneously under pressure by direct injection, application, or the like. Alternatively, the composition may be administered or provided in the form of a composition that is applied to the skin after the patient has taken a bath or before going to bed, a form for application that penetrates into the skin, an adhesive form such as a compress or sticker, or a composition contained in an object that comes into contact with the skin, such as clothing or sheets.
[0026] In the method for treating bedsore according to an embodiment of the present invention, the administration interval and administration amount of the bedsore treatment agent containing the IL-33 inhibitor of this embodiment can be appropriately selected and changed depending on various conditions such as the state of the disease and the condition of the subject. More specifically, by subcutaneously administering the pressure ulcer treatment agent of the present embodiment as soon as possible after pressure loading or after the onset of erythema, it is possible to suppress the inflammation enhancing action caused by IL-33 and suppress the onset of ulcer. This administration may be performed, for example, at intervals of several hours to several days, or may be continuously administered by application of a liniment, depending on the effective period of the IL-33 inhibitor. Furthermore, by administering the agent for treatment after the onset of ulcer, it is possible to suppress the progression of ulcer expansion and contribute to early treatment.
[0027] The single dose and frequency of administration of the bedsore treatment agent according to the embodiment of the present invention can be appropriately selected and changed depending on the purpose of administration, as well as various conditions such as the patient's age and weight, and the symptoms and severity of the disease. The number of administrations and the duration of administration may be just once after pressure overload, or it may be administered once to several times a day for about several weeks, and the condition of the disease may be monitored, and administration may be repeated or repeated depending on the condition. Furthermore, when the bedsore treating agent of this embodiment is contained in an application agent or an object that comes into contact with the skin, the patient may be able to treat the bedsore by himself / herself as a non-medical procedure without relying on a doctor or nurse.
[0028] In addition, the method for treating bedsores according to the embodiment of the present invention can also be applied to animal treatment. The animals are not particularly limited and include a wide range of vertebrates and invertebrates. The vertebrates include fish, amphibians, reptiles, birds, and mammals. Specifically, the mammals may be, for example, rodents such as mice, rats, ferrets, hamsters, guinea pigs, or rabbits, dogs, cats, sheep, pigs, cows, horses, or non-human transgenic primates. In addition to mammals, wild animals include fish, birds including poultry, and reptiles. In addition, crustaceans including shrimp and insects, and other invertebrates such as squids are also widely included. That is, the therapeutic agent for bedsore according to the embodiment of the present invention can be used not only for the treatment of humans, but also for the treatment of various animals and for the promotion of growth of livestock.
[0029] [Methods for preventing bedsores] The method for preventing bedsores according to the embodiment of the present invention is characterized by administering an IL-33 inhibitor that inhibits the action of IL-33 (Interleukin-33). In the method for preventing bedsores according to the present embodiment, the above-mentioned bedsore treatment agent is administered prophylactically before ulcer formation due to bedsores. In this case, too, the patient can administer the agent himself / herself, which is different from medical treatment by a doctor or nurse. That is, the method for preventing bedsores according to the present embodiment can be realized by administration in a broad sense, for example, by over-the-counter medicines not prescribed by a doctor, application of over-the-counter liniments, acquisition as a general medicine, or clothing that prevents bedsores. That is, by administering the IL-33 inhibitor of this embodiment so as to suppress the formation of bedsores, it is possible to prevent the formation of ulcers in bedsores and prevent the deterioration of bedsores.
[0030] With the above configuration, the following effects can be obtained. Conventionally, the focus of attention has been on neutrophils and vascular endothelial cells in the reperfusion injury that causes bedsores, and free radicals and intracellular Ca 2+ Although transient activation of blood vessel overload, cytokines, and adhesion molecules has been suggested, the true target molecules that cause reperfusion injury have yet to be identified. Conventional treatment methods for bedsore include the use of basic fibroblast growth factor sprays, prostaglandin ointments, and various wound dressings to treat skin ulcers after they have formed. However, conservative treatment of bedsores once they have developed is very difficult. Surgical treatment is also often difficult depending on the patient's overall condition. On the other hand, it is known that the healing of skin ulcers is delayed in IL-33 knockout mice compared to wild-type mice. IL-33 is also involved in epidermal migration and proliferation, and it was previously concluded that IL-33 promotes the healing of skin ulcers by promoting epidermal cell proliferation and migration and by suppressing inflammation via NFκB. For this reason, those skilled in the art have believed that IL-33 may also have a promoting effect on the healing process of bedsores.
[0031] In response to this, the present inventors have demonstrated, as shown in the Examples described below, that IL-33 plays an important role in the formation stage of skin ulcers caused by pressure load, contrary to the assumption of those skilled in the art. Based on this, the present embodiment of the treatment for bedsores can be provided as a drug for preventing bedsore formation and for treating bedsores early by inhibiting IL-33. In this way, by inhibiting IL-33, it is possible to suppress the occurrence of bedsores and the progression of ulcer formation, treat bedsores, and promote healing. This makes it possible to treat bedsores conservatively, which was previously difficult. In addition, it will be possible to treat patients whose general condition makes surgical treatment difficult. In other words, it is expected that bedsores will be treated using a mechanism different from that of conventional techniques. In addition, since bedsore formation was also suppressed by a neutralizing antibody that neutralizes IL-33 itself as a cytokine, the bedsore treatment agent of this embodiment can treat and prevent ulcer formation after pressure overload or erythema by inactivating extracellular IL-33.
[0032] Furthermore, it has been known that IL-33 has a dual role: it acts as a cytokine outside the cell and also acts as a nuclear factor inside the cell. In this regard, since the formation of bedsores was suppressed when a soluble ST2 transgenic mouse was used as described in the Examples below, it is believed that the involvement of IL-33 in the formation of bedsores is mainly due to its action as an extracellular cytokine. Therefore, the IL-33 inhibitor of this embodiment, by containing an ST2 inactivator, can be effectively used for the treatment and prevention of bedsores. That is, for example, for a receptor such as ST2, a small organic compound that can be chemically synthesized can be selected by a routine drug screening process, and this can be used to create a medicine that can be widely used for treating bedsores and skin diseases.
[0033] That is, as shown in the Examples below, by administering a neutralizing antibody to IL-33 or a neutralizing antibody to the IL-33 receptor, etc. to local skin, it is possible to suppress the formation of bedsores at that site. A certain number of bedsores exist wherever there are hospital beds, and the number of elderly people requiring nursing care is expected to increase in the future. For this reason, it is expected that the bedsore treatment agent of the present embodiment will be widely used in society.
[0034] The therapeutic agent for bedsore of the present embodiment can also be used for experimental purposes on bedsore model animals, which is expected to clarify the pathology of bedsore. That is, it can also be used for experiments and models of the mechanism of action in bedsores in animals.
[0035] Additionally, in the treatment agent for bedsore, the method for treating bedsore, and the method for preventing bedsore of this embodiment, it is also possible to carry out gene therapy via the action of IL-33 on genes or pathways whose expression is regulated.
[0036] The bedsore treating agent according to the embodiment of the present invention can also be used in combination with other compositions, etc. The composition of the present invention may be administered, sprayed, applied, etc., simultaneously with other compositions. Furthermore, the IL-33 inhibitor of this embodiment can also be used for purposes other than medicine. EXAMPLES
[0037] The IL-33 inhibitor according to the embodiment of the present invention will be described in more detail below as an example based on a specific experiment. However, this example is merely an example and is not intended to be limiting.
[0038] Materials and Methods (mouse) BALB / c mice were used. IL-33 knockout mice were used that were created in the laboratory of one of the present inventors, Susumu Nakae. ST2 transgenic mice were used that were owned by the Department of Pathological Biochemistry, Jichi Medical University. Wild-type BALB / c mice were used that were purchased from CLEA Japan, Inc.
[0039] (Reagents used) The neutralizing antibodies used were IL-33 neutralizing antibody (Adipogen, AG-27B-0013PF, Protein Accession No: Q8BVZ5) or ST2 neutralizing antibody (Medical and Biological Laboratories, Anti-ST2 (Human) mAb, Code No. D065-3).
[0040] (Pressure load test procedure) The procedure for the pressure overload test in this embodiment will be described with reference to FIG. In this example, as a pressure overload test, the state of skin ulcer formation after pressure overloading with a magnet on the back of a mouse, which is used by those skilled in the art as a bedsore mouse model, was observed. Specifically, the back of the mouse was shaved, and a certain amount of pressure was applied by pinching the skin and clamping it with a circular magnet. After 12 hours, the magnet was removed, and the area of the ulcer formed thereafter was measured. Specifically, a comparison was made between IL-33 knockout mice, ST2 transgenic mice, and control wild-type mice.
[0041] (Administration of neutralizing antibodies) In the pressure overload test, 2.5 μg / mouse of IL-33 neutralizing antibody or 10 μg / mouse of ST2 neutralizing antibody was diluted with PBS (Phosphate Buffered Saline) and administered by subcutaneous injection into the local skin once every two days from the time of removing the magnet. At this time, as controls, a group administered only PBS or a group administered 10 μg / mouse of rat IgG were also administered.
[0042] 〔result〕 (IL-33 knockout mice) The results of the pressure overload test in IL-33 knockout mice will be explained with reference to Figures 3 and 4. Figure 3(a) shows the state of a control wild-type mouse (WT mouse), and Figure 3(b) shows the state of an IL-33 knockout mouse (IL-33KO mouse) after pressure overload testing. The state is shown from day 2 (D2) to day 14 (D14) after surgery. In each photograph, the area of the ulcer, where the area was measured, is shown surrounded by a light-colored line. Figure 4 is a graph showing the area of the ulcer. The horizontal axis shows the number of days after treatment, and the vertical axis shows the area of the ulcer (mm 2 ) (n=20). In the graph, "*" indicates P<0.05 and "**" indicates P<0.01, which are statistically significant.
[0043] In wild-type mice, after pressure was released, ulcers did not form immediately, but gradually the skin necrotized and ulcers formed. The ulcer area peaked on the 8th day, after which healing progressed and the area tended to become epithelialized, and by the 14th day it was completely epithelialized. The ulcer area was smaller in the IL-33 knockout mice than in the wild-type mice. Specifically, ulcer formation was significantly suppressed in the IL-33 knockout mice, with almost no ulcer formation observed. In other words, the formation of ulcers due to pressure overload was suppressed in the IL-33 knockout mice.
[0044] (ST2 transgenic mice) Next, the results of the pressure overload test in ST2 transgenic mice will be explained with reference to FIGS. Figure 5(a) shows the state of a control wild-type mouse (WT mouse) and Figure 6(b) shows the state of an ST2 transgenic mouse (ST2Tg mouse) after pressure overload testing. Each shows the condition 2 days (D2) to 14 days (D14) after surgery. In each photograph, the area of the ulcer, where the area was measured, is shown surrounded by a light-colored line. FIG. 6 is a graph showing the area of the ulcer. The horizontal axis indicates the number of days after the procedure (day 2 to day 14), and the vertical axis indicates the area of the ulcer (mm 2 ) (n=16). In the graph, "*" indicates P<0.05 and "**" indicates P<0.01, which are statistically significant.
[0045] Here, soluble ST2 is a molecule having a structure consisting only of the extracellular portion of ST2L, the IL-33 receptor, and by binding to IL-33, it inhibits IL-33 from binding to the receptor and transmitting a signal into the cell. The ST2 transgenic mouse of this example is a mouse that overexpresses soluble ST2, and it is believed that the excess soluble ST2 inhibits the function of IL-33 as a cytokine. As a result, pressure-induced bedsore formation was significantly suppressed in ST2 transgenic mice compared to wild-type mice.
[0046] (Administration of IL-33 neutralizing antibody) Next, the results of the pressure overload test when IL-33 neutralizing antibody was administered will be explained with reference to FIG. 7 and FIG. Figure 7(a) shows the state of a control BALB / c mouse administered only PBS, and Figure 7(b) shows the state of a BALB / c mouse administered an IL-33 neutralizing antibody after a pressure overload test. Each shows the state from day 3 (D3) to day 13 (D13) after the procedure. Figure 8 is a graph showing the area of the ulcer. The horizontal axis shows the number of days after treatment, and the vertical axis shows the area of the ulcer (mm 2 ) (n=5). "*" in the graph indicates P<0.05, which is statistically significant.
[0047] As a result, administration of IL-33 neutralizing antibody suppressed ulcer formation caused by pressure overload. IL-33 neutralizing antibody binds to IL-33 and inhibits IL-33 from transmitting signals into cells via its receptor. By administering this IL-33 neutralizing antibody subcutaneously once every two days from the time pressure overload was released, bedsore formation was significantly suppressed compared to the control.
[0048] (ST2 neutralizing antibody administration) Next, the results of the pressure overload test when ST2 neutralizing antibody was administered will be described with reference to FIG. 9 and FIG. Figure 9(a) shows the condition of a control BALB / c mouse administered with a rat IgG antibody, and Figure 9(b) shows the condition of a BALB / c mouse administered with an ST2 neutralizing antibody after a pressure overload test. Each shows the condition 2 days (D2) to 14 days (D14) after the procedure. Figure 10 is a graph showing the area of the ulcer. The horizontal axis shows the number of days after treatment, and the vertical axis shows the area of the ulcer (mm 2 ) (n=6). In the graph, "*" indicates P<0.05, "**" indicates P<0.01, and "***" indicates P<0.001, which are statistically significant.
[0049] As a result, administration of the ST2 neutralizing antibody suppressed ulcer formation caused by pressure overload. The ST2 neutralizing antibody used in the test binds to the IL-33 receptor (ST2L) and inhibits IL-33 from transmitting signals into cells via the receptor. By administering this ST2 neutralizing antibody subcutaneously once every two days from the time pressure was released, the formation of pressure ulcers was significantly suppressed compared to the wild type.
[0050] It goes without saying that the configurations and operations of the above-described embodiments are merely examples and can be modified as appropriate without departing from the spirit and scope of the present invention. [Industrial Applicability]
[0051] According to the present invention, by using an IL-33 inhibitor for the treatment of bedsores, it is possible to prevent the early formation of bedsores and provide a medicine for treatment, thereby providing a method for treating and preventing bedsores, and therefore the present invention is industrially applicable.
Claims
1. An IL-33 inhibitor that inhibits the action of IL-33 (Interleukin-33), The IL-33 inhibitors are an anti-IL-33 neutralizing antibody, an IL-33 binding site of ST2, and an anti-ST2 neutralizing antibody. A treatment for bedsores, comprising:
2. The IL-33 inhibitor inactivates extracellular IL-33 or inactivates the IL-33 receptor on the cell membrane. The treatment for bedsores according to claim 1 .
3. The IL-33 inhibitor includes an IL-33 activity inhibitor or an IL-33 expression inhibitor. The treatment for bedsores according to claim 1 or 2.
4. The IL-33 receptor is ST2. The treatment for bedsores according to claim 2 .
5. The IL-33 inhibitor comprises an inactivator of ST2. The treatment for bedsores according to claim 4 .
6. Administered prophylactically before pressure sore ulcers form, or administered therapeutically after ulcers have developed The treatment for bedsores according to claim 1 .
Citation Information
Patent Citations
Human Anti-il-33 neutralizing monoclonal antibody
JP2017008003A
anti-inflammatory polypeptide
JP2018508522A
Biomarkers for interleukin-33 (il-33)-mediated diseases and their uses
JP2018533557A
New metal complexes of nocardamine and their use in pharmaceutical compositions
JP2020023558A
Methods for treating inflammatory conditions
JP2020513404A
